Appl. N.

Filed

January 7, 1997

02

6. (Amended) The [immunomodulating agent of claim 1] composition of Claim 66 wherein said [at least one Fc receptor ligand] immunoglobulin or portion thereof comprises at least part of a domain of a constant region of an immunoglobulin molecule.

(Amended) The Immunomodulating agent of claim 11 composition of Claim-66 wherein the [immunomodulating agent comprises an antibody-antigen complex] composition comprises a complex between said immunoglobulin or portion thereof and said protein fragment or peptide.

(Amended) The [immunomodulating agent of claim 1] composition of Claim 66 wherein the [immunomodulating agent] composition is a chimeric antibody in which said protein fragment or peptide is covalently joined to said immunoglobulin or portion thereof in a single <u>molecule</u>.

a6

a8

(Amended) The [immunomodulating agent of claim 10] composition of Claim 9 wherein the protein fragment or peptide comprising said T cell receptor antagonist is [expressed] positioned within at least one complementarity determining region to partially or fully replace said complementarity determining region.

-protein.

- (Amended) The composition of claim [23] 67 wherein said T cell receptor antagonist is an analog of a peptide agonist capable of activating a T cell response to proteolipid
- (Amended) The composition of claim [22] 67 wherein said [Fc receptor ligand] 26. immunoglobulin or portion thereof comprises at least part of one domain of a constant region of an immunoglobulin molecule.
- 27. (Amended) The composition of claim 26 wherein the immunoglobulin [molecule] or portion thereof is a human IgG molecule or portion thereof.

(Amended) The composition of claim [22] 67 wherein said [immunomodulating agent] composition comprises a chimeric antibody in which said protein fragment or peptide is covalently joined to said immunoglobulin or portion thereof in a single molecule.

Please add the following new claims.

A composition comprising an immunoglobulin or a portion thereof linked to a rotein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding